Acne Vulgaris Market Report 2026

The acne vulgaris market size has grown strongly in recent years. It will grow from $8.44 billion in 2025 to $8.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of acne vulgaris among adolescents, rising awareness of dermatological treatments, expansion of hospital and clinic networks, availability of prescription acne medications, growing cosmetic and skincare awareness.

The acne vulgaris market size is expected to see strong growth in the next few years. It will grow to $11.46 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to development of targeted acne therapeutics, increasing adoption of teledermatology and digital health platforms, growth in anti-inflammatory and retinoid formulations, rising demand for personalized skincare regimens, expansion of online pharmacy and e-commerce channels. Major trends in the forecast period include rising demand for combination topical therapies, increasing adoption of hormonal treatments in acne management, growth in laser and light-based physical treatments, expansion of oral retinoids and antibiotic therapies, rising preference for herbal, natural, and emerging therapies.

The increasing demand for skincare products is expected to drive the growth of the acne vulgaris market in the coming years. Skincare products are formulations designed to improve the health and appearance of the skin. They encompass a wide range of items that address various skin concerns, including cleansing, moisturizing, and protection. The rising demand for skincare products is fueled by social media influence, increasing dermatological concerns, product innovations, and a shift toward preventive skincare, which has heightened awareness of skin health. Skincare products support acne vulgaris treatment by targeting the underlying causes of the condition, such as excess sebum production, clogged pores, and bacterial growth, using ingredients like salicylic acid, benzoyl peroxide, and retinoids to exfoliate the skin, reduce inflammation, and promote clearer, healthier skin. For instance, in August 2024, data from The Cosmetic, Toiletry and Perfumery Association (CTPA), a UK-based non-profit organization, indicated that the European cosmetics market was valued at €96 billion (approximately $105 billion) at retail sales price (RSP) in 2023, making it one of the largest markets globally alongside the USA. This marked growth from €88 billion (approximately $93 billion) RSP in 2022. Therefore, rising awareness of skincare is contributing to the growth of the acne vulgaris market.

Major companies operating in the acne vulgaris market are focusing on developing innovative solutions, such as triple-combination topical treatments, to offer a simplified, once-daily approach for managing acne vulgaris. A triple-combination topical treatment is a formulation that combines three active ingredients, typically targeting different aspects of a condition, to provide enhanced therapeutic effects in treating skin disorders like acne or psoriasis. For instance, in October 2023, Bausch Health Companies Inc., a Canada-based pharmaceutical company, announced FDA approval for Cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide). This topical gel is designed for patients aged 12 years and older to treat acne vulgaris. The formulation combines an antibiotic, a retinoid, and an antibacterial agent to effectively target acne lesions and prevent future breakouts. Cabtreo provides a convenient application method and demonstrates a favorable safety profile for a wide range of patients.

In September 2023, Glenmark Specialty SA, an India-based pharmaceutical company, announced a partnership with Cosmo Pharmaceuticals to strengthen its dermatology portfolio and address unmet medical needs in acne treatment. The partnership aims to expand the availability of Winlevi (clascoterone cream 1%) across 15 EU countries, South Africa, and the UK, responding to the growing demand for innovative acne treatments. Cosmo Pharmaceuticals NV is an Ireland-based pharmaceutical company that specializes in topical treatments for acne vulgaris.

Major companies operating in the acne vulgaris market are Pfizer Inc., Johnson and Johnson, AbbVie Inc., L'Oréal Paris, GlaxoSmithKline Plc., Reckitt Benckiser Group plc, Viatris Inc., Teva Pharmaceuticals, Bausch Health Companies, Sun Pharmaceutical Industries Ltd., Incyte, Aurobindo Pharma, Lupin Ltd., Torrent Pharmaceuticals, Biocon, Stiefel Laboratories, Mayne Pharma Group Limited, Paratek Pharmaceuticals, Cosmo Pharmaceuticals, AOBiome.

North America was the largest region in the acne vulgaris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acne vulgaris market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acne vulgaris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acne vulgaris market by raising the cost of imported dermatological formulations, active pharmaceutical ingredients (APIs), and laser treatment devices. Segments such as systemic therapy medications, topical combination therapies, and physical treatment devices are most affected, particularly in regions like north america, europe, and asia-pacific. These tariffs have resulted in increased treatment costs and supply chain adjustments. On the positive side, they have encouraged local manufacturing, innovation in cost-effective acne treatments, and the development of domestic skincare product lines.

The acne vulgaris market research report is one of a series of new reports that provides acne vulgaris market statistics, including acne vulgaris industry global market size, regional shares, competitors with a acne vulgaris market share, detailed acne vulgaris market segments, market trends and opportunities, and any further data you may need to thrive in the acne vulgaris industry. This acne vulgaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acne vulgaris is a common chronic inflammatory skin disorder primarily affecting the pilosebaceous units. It is characterized by the formation of comedones, papules, pustules, nodules, and cysts, often triggered by factors such as excess sebum production, follicular hyperkeratinization, Cutibacterium acnes proliferation, and inflammation. It typically occurs on the face, chest, and back, with severity varying and potential for scarring.

The primary treatment types for acne vulgaris include systemic therapy, hormonal therapy, physical treatment, topical combination therapy, and others. Systemic therapy is an approach that affects the entire body by delivering medication through the bloodstream and is commonly used for conditions such as cancer, autoimmune diseases, and infections. Treatments are categorized by age group, including 10 to 17 years, 18 to 44 years, 45 to 64 years, and 65 years and above, and are distributed through channels such as hospital pharmacies and online pharmacies.

The acne vulgaris market consists of sales of topical retinoids, oral retinoids, benzoyl peroxide formulations, oral antibiotics, hormonal therapies, and salicylic acid-based treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.